Journal Home
Search for

Volume 1, Issue 6, Pages 593-598 (December 2007)


View previous. 8 of 17 View next.

Free oxygen radicals in whole blood correlate strongly with high-sensitivity C-reactive protein

Matthey T. Harris, MDa, Warren W. Davis, MDb, Ngoc-Anh Le, PhDaCorresponding Author Informationemail address, Barry Eggleston, PhDc, Garth E. Austin, MD, PhDb, Mohamad Moussa, MDb, W. Virgil Brown, MDa

Received 10 October 2007; accepted 12 October 2007. published online 22 October 2007.

Background

Increased concentrations of reactive oxygen molecules are believed to be a driving force in inflammation. Although evident in tissue culture and animal models, it has been difficult to link reactive oxygen species (ROS) and inflammatory markers in humans. In patients recruited to represent a broad spectrum of risk factors, we investigated the relationship between the plasma concentration of oxygen radicals and high-sensitivity C-reactive protein (hs-CRP), utilizing a new chemistry with an easily oxidized chromophore.

Methods

ROS and hs-CRP were measured in blood from 59 fasting subjects selected to have variable risk predicted by classical risk factors. ROS were determined using the free oxygen radical monitor, which is an indirect colorimetric assay for the concentration of hydroperoxides in whole blood.

Results

Using log transformation, the correlation between ROS and hs-CRP was r = 0.505 (P < 0.0001). This relationship between ROS and hs-CRP was comparable (r = 0.527, P = 0.001) in the subgroup not currently on statin therapy (n = 39). ROS were not correlated with Framingham risk, r = −0.027 (P = 0.84).

Conclusion

ROS directly measured in human blood correlates strongly with hs-CRP.

a Emory University School of Medicine, 1670 Clairmont Road, Mail Code 151, Decatur, GA 30033, USA

b Atlanta VA Medical Center, Atlanta, GA, USA

c Rho Incorporated, Chapel Hill, NC, USA

Corresponding Author InformationCorresponding author.

PII: S1933-2874(07)00290-5

doi:10.1016/j.jacl.2007.10.008


View previous. 8 of 17 View next.